Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALUR
Upturn stock ratingUpturn stock rating

Allurion Technologies, Inc. (ALUR)

Upturn stock ratingUpturn stock rating
$2.43
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ALUR (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

4 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $10.62

1 Year Target Price $10.62

Analysts Price Target For last 52 week
$10.62Target price
Low$2.15
Current$2.43
high$33.75

Analysis of Past Performance

Type Stock
Historic Profit -42.66%
Avg. Invested days 34
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 18.12M USD
Price to earnings Ratio -
1Y Target Price 10.62
Price to earnings Ratio -
1Y Target Price 10.62
Volume (30-day avg) 4
Beta -0.51
52 Weeks Range 2.15 - 33.75
Updated Date 06/30/2025
52 Weeks Range 2.15 - 33.75
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -14.22

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -86.05%
Operating Margin (TTM) -130.5%

Management Effectiveness

Return on Assets (TTM) -52.2%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 30689351
Price to Sales(TTM) 0.64
Enterprise Value 30689351
Price to Sales(TTM) 0.64
Enterprise Value to Revenue 1.08
Enterprise Value to EBITDA -2.15
Shares Outstanding 7457760
Shares Floating 3680180
Shares Outstanding 7457760
Shares Floating 3680180
Percent Insiders 11.67
Percent Institutions 46.23

Analyst Ratings

Rating 2
Target Price 10.62
Buy 1
Strong Buy 2
Buy 1
Strong Buy 2
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Allurion Technologies, Inc.

stock logo

Company Overview

overview logo History and Background

Allurion Technologies, Inc. focuses on developing innovative solutions for weight loss. Founded in 2009, it gained prominence with its swallowable gastric balloon program.

business area logo Core Business Areas

  • Weight Loss Program: Allurion's flagship product is a weight-loss program centered on its swallowable gastric balloon, coupled with nutritional and lifestyle support. The Allurion Program provides access to a mobile app, connected scale, and health tracker.

leadership logo Leadership and Structure

The leadership team is headed by its Chief Executive Officer. The structure comprises departments for R&D, marketing, sales, and operations.

Top Products and Market Share

overview logo Key Offerings

  • Allurion Program: The Allurion Program features a swallowable gastric balloon inserted without surgery, endoscopy, or anesthesia, coupled with a lifestyle change program, supported by connected tools and virtual care. Revenue is largely derived from the Allurion Program. Competitors include other medical weight loss programs and bariatric surgeries. There is no specific market share available, as this is a niche segment of weight loss.

Market Dynamics

industry overview logo Industry Overview

The weight loss industry is driven by the increasing prevalence of obesity and related health concerns. It includes diet programs, weight loss surgeries, medical devices, and pharmaceuticals.

Positioning

Allurion positions itself as a non-surgical weight loss solution, differentiating from bariatric surgery and intensive medical interventions.

Total Addressable Market (TAM)

The global weight management market is expected to reach hundreds of billions of dollars. Allurion targets a segment of this market, focusing on individuals seeking less invasive weight loss options.

Upturn SWOT Analysis

Strengths

  • Non-surgical approach
  • Innovative technology (swallowable balloon)
  • Comprehensive program (balloon + support)
  • Global presence

Weaknesses

  • Cost compared to diet programs
  • Reliance on program adherence
  • Potential side effects
  • Limited long-term data

Opportunities

  • Expanding into new markets
  • Developing new products
  • Partnerships with healthcare providers
  • Increased awareness of non-surgical options

Threats

  • Competition from other weight loss methods
  • Regulatory changes
  • Economic downturn
  • Negative publicity

Competitors and Market Share

competitor logo Key Competitors

  • ResMed (RMD)
  • Novo Nordisk (NVO)
  • Intuitive Surgical (ISRG)

Competitive Landscape

Allurion's advantage is its non-surgical approach. Disadvantages include cost and the need for patient compliance.

Growth Trajectory and Initiatives

Historical Growth: The growth rate is dependent on market adoption and expansion into new regions.

Future Projections: Future growth is dependent on analyst estimates and company guidance which can be located on the company's IR page.

Recent Initiatives: Recent strategic initiatives typically include market expansion, product development, and partnerships.

Summary

Allurion Technologies, Inc. offers an innovative, non-surgical weight loss solution with global reach. Its strengths lie in its unique technology and comprehensive program, but it faces challenges related to cost, patient compliance, and competition. Future success depends on expanding into new markets, developing new products, and forging strategic partnerships. However the smaller market share will need to increase for better margins and ROI for shareholders

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Company Website
  • Analyst Reports
  • Press Releases

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market share figures are estimates and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Allurion Technologies, Inc.

Exchange NYSE
Headquaters Natick, MA, United States
IPO Launch date 2023-08-02
Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director Dr. Shantanu K. Gaur M.D.
Sector Healthcare
Industry Medical Devices
Full time employees 134
Full time employees 134

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform offers the Allurion Program, a swallowable and procedure-less intragastric balloon for weight loss, as well as provides access to artificial intelligence-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company operates in Spain, France, Turkey, and internationally. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.